Skip to main content
OpenTrials
Completed

NCT Number: NCT03616717

Modafinil Effects on EEG Biomarkers of Reward and Motivation

The effects of modafinil on measures of brain electrical activity will be tested.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Adults

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of California, San Diego; Clinical Teaching Facilities, Hillcrest

San Diego, California, 92103, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Exclusion criteria

  • history of substance abuse
  • mental illness in a first degree relative
  • significant medical illness (e.g. cancer, diabetes, heart disease, HIV)
  • history of seizure
  • open head injury or closed head injury with loss of consciousness > 1 min
  • pregnancy
  • current psychotropic drug use
  • R-hand injury
  • hearing or visual impairment
  • urine toxicology positive for recreational drug use

Treatment and study plan

Modafinil

Drug

Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.

Other Names:

Provigil Alertec Modavigil

Placebo

Drug

Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.

Primary outcomes

  1. Reward Positivity

    Time frame: 1 year

    Frontal alpha power by block in the probabilistic learning task

  2. Motivation Signal

    Time frame: 1 year

    Parietal EEG alpha power peak in first - final step toward breakpoint

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Registry information

Official study title

Neurophysiological Biomarkers of Behavioral Dimensions From Cross-species Paradigms

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Aug 6, 2018
Registry last updated
Apr 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.